Regulus Therapeutics Inc. (NASDAQ:RGLS) was down 11.2% on Thursday . The stock traded as low as $3.57 and last traded at $3.64, with a volume of 606,409 shares changing hands. The stock had previously closed at $4.10.

Several equities research analysts recently weighed in on RGLS shares. BMO Capital Markets started coverage on shares of Regulus Therapeutics in a research report on Monday, April 11th. They set an “outperform” rating and a $16.00 price target for the company. Chardan Capital started coverage on shares of Regulus Therapeutics in a research report on Wednesday, April 13th. They set a “buy” rating and a $15.00 price target for the company. Wedbush reissued an “outperform” rating and set a $48.00 price target on shares of Regulus Therapeutics in a research report on Friday, April 15th. FBR & Co reissued a “buy” rating and set a $30.00 price target on shares of Regulus Therapeutics in a research report on Sunday, April 17th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Regulus Therapeutics in a research report on Tuesday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $10.17.

The company has a 50 day moving average price of $4.10 and a 200-day moving average price of $5.82. The company’s market capitalization is $188.43 million.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. On average, analysts expect that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.